New Pyrimidinone and Fused Pyrimidinone Derivatives as Potential Anticancer Chemotherapeutics
作者:Aymn E. Rashad、Ahmed H. Shamroukh、Nabil M. Yousif、Mowafia A. Salama、Hatem S. Ali、Mamdouh M. Ali、Abeer E. Mahmoud、Mahmoud El-Shahat
DOI:10.1002/ardp.201200119
日期:2012.9
of novel substituted pyrimidinones and fused pyrimidinones (compounds 3–18) were synthesized starting with oxiranylmethanone 2. The in vitro cytotoxicity against a human breast adenocarcinoma (MCF‐7) cell line was investigated and most of the tested compounds showed potent cytotoxic activity against the MCF‐7 cell line comparable to the activity of the commonly used anticancer drug cisplatin. Treatment
以环氧乙烷基甲酮 2 为起始原料合成了一系列新型取代嘧啶酮和稠合嘧啶酮(化合物 3-18)。研究了对人乳腺癌 (MCF-7) 细胞系的体外细胞毒性,大多数测试化合物显示出有效的细胞毒性活性针对 MCF-7 细胞系的活性与常用的抗癌药物顺铂的活性相当。用增加剂量(2、5、10 和 20 µg/mL)的测试化合物处理 MCF-7 细胞显示超氧化物歧化酶的活性和过氧化氢水平显着增加,而过氧化氢酶和谷胱甘肽的活性与对照 MCF-7 细胞相比,过氧化物酶和还原型谷胱甘肽的水平显着降低。一般来说,